Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

Name: Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Published: 2020
License: Public Domain

Jazz Pharmaceuticals · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

coronavirus-disease-2019-covid-19 sars-cov-2

coronavirus disease 2019 (covid-19), acute lung injury, severe acute respiratory syndrome coronavirus 2 (sars-cov-2), covid-19, ali, sars-cov-2, interventional, phase2, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

Related documents